<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
		>
<channel>
	<title>Comments for KinasePro</title>
	<atom:link href="http://kinasepro.wordpress.com/comments/feed/" rel="self" type="application/rss+xml" />
	<link>http://kinasepro.wordpress.com</link>
	<description>Kinase Chemistry - Just a year and a half behind the times.</description>
	<lastBuildDate>Thu, 29 Apr 2010 18:16:49 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
	<item>
		<title>Comment on LY333531 / Arxxant by Jim Kerhin</title>
		<link>http://kinasepro.wordpress.com/2006/11/13/ly333531-arxxant/#comment-31970</link>
		<dc:creator><![CDATA[Jim Kerhin]]></dc:creator>
		<pubDate>Thu, 29 Apr 2010 18:16:49 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2006/11/13/ly333531-arxxant/#comment-31970</guid>
		<description><![CDATA[I was a test subject (type1 since 1975) for ly333531 from about 2001-2003?? in Milwaukee. I believe they were studying Macular Edema. I had a little but it seemed to have been stopped during the study period and for a few years after. I&#039;d sure like to know more about getting some more. I&#039;m a believer!]]></description>
		<content:encoded><![CDATA[<p>I was a test subject (type1 since 1975) for ly333531 from about 2001-2003?? in Milwaukee. I believe they were studying Macular Edema. I had a little but it seemed to have been stopped during the study period and for a few years after. I&#8217;d sure like to know more about getting some more. I&#8217;m a believer!</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on iKinase by partial agonist</title>
		<link>http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31968</link>
		<dc:creator><![CDATA[partial agonist]]></dc:creator>
		<pubDate>Mon, 19 Apr 2010 18:55:02 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31968</guid>
		<description><![CDATA[Has this blog died?  Sad... this was one of my faves!]]></description>
		<content:encoded><![CDATA[<p>Has this blog died?  Sad&#8230; this was one of my faves!</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on iKinase by zegez</title>
		<link>http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31967</link>
		<dc:creator><![CDATA[zegez]]></dc:creator>
		<pubDate>Sun, 18 Apr 2010 13:24:39 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31967</guid>
		<description><![CDATA[Whats this]]></description>
		<content:encoded><![CDATA[<p>Whats this</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Steal This Document by singh</title>
		<link>http://kinasepro.wordpress.com/2007/10/10/steal-this-document/#comment-31966</link>
		<dc:creator><![CDATA[singh]]></dc:creator>
		<pubDate>Sat, 17 Apr 2010 02:34:06 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2007/10/10/steal-this-document/#comment-31966</guid>
		<description><![CDATA[can&#039;t see the spreadsheet!...
ALso any way you will be publishing this list (updated 2010)?]]></description>
		<content:encoded><![CDATA[<p>can&#8217;t see the spreadsheet!&#8230;<br />
ALso any way you will be publishing this list (updated 2010)?</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on ENMD-2076 by George</title>
		<link>http://kinasepro.wordpress.com/2009/07/31/enmd-2076/#comment-31965</link>
		<dc:creator><![CDATA[George]]></dc:creator>
		<pubDate>Sat, 03 Apr 2010 11:53:05 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/?p=1291#comment-31965</guid>
		<description><![CDATA[Oh, I almost forgot.

ENMD-2076 must be doing good in the Multiple Myeloma trial because one year into the trial the US National Institute for Health thru the National Cancer Institute has agreed to fund a grant to study for ENMD-2076 as a treatment for Multiple Myeloma.

Sherif Shafik Farag NIH-NCI New Multiple kinase target inhibition with EMND-2076 in multiple myeloma 2/1/10 1/31/11 319,550 

http://scope.medicine.iu.edu/archives/2010/Vol-14-No-9.htm

Good luck and GOD bless,

George]]></description>
		<content:encoded><![CDATA[<p>Oh, I almost forgot.</p>
<p>ENMD-2076 must be doing good in the Multiple Myeloma trial because one year into the trial the US National Institute for Health thru the National Cancer Institute has agreed to fund a grant to study for ENMD-2076 as a treatment for Multiple Myeloma.</p>
<p>Sherif Shafik Farag NIH-NCI New Multiple kinase target inhibition with EMND-2076 in multiple myeloma 2/1/10 1/31/11 319,550 </p>
<p><a href="http://scope.medicine.iu.edu/archives/2010/Vol-14-No-9.htm" rel="nofollow">http://scope.medicine.iu.edu/archives/2010/Vol-14-No-9.htm</a></p>
<p>Good luck and GOD bless,</p>
<p>George</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on ENMD-2076 by George</title>
		<link>http://kinasepro.wordpress.com/2009/07/31/enmd-2076/#comment-31964</link>
		<dc:creator><![CDATA[George]]></dc:creator>
		<pubDate>Sat, 03 Apr 2010 11:22:31 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/?p=1291#comment-31964</guid>
		<description><![CDATA[How many other kinase inhibitors potently affect as many different kinases and cancer types?

********************************************************************************

Striking response in just 7 days for AML leukemia:

&quot;...This patient #106, who has a FLT3-ITD mutation, showed a striking reduction in the percentage of circulating blast cells after 7 days treatment with ENMD-2076....&quot;

&quot;...A second patient, #120, has a signaling profile very similar to #106,and early follow up indicates that this patient has also had a major response...&quot;

http://www.entremed.com/files/enmd_poster_aacr09_p1_leukemia_final_web.pdf

*******************************************************************************

Including ovarian cancer:

Watch the video

http://staging.kusa.com/seenon9news/article.aspx?storyid=128349


&quot;...&quot;I&#039;m excellent, life is fabulous,&quot; she told a nurse at the University of Colorado Cancer Center....&quot;

&quot;...Thornton and Messersmith were surprised to find the drug known as ENMD-2076 is working well for ovarian cancer patients involved in the study. 

&quot;We have your counts back and they look great,&quot; Messersmith said to Thornton during a checkup. 

&quot;This is what gets us all up in the morning, to see someone take advantage of it and live life to the fullest,&quot; Messersmith said....&quot;

*********************************************************************************

&quot;...Clinical benefit has been demonstrated with reductions in tumor volume,
reductions in tumor markers, and improvement in cancer-related symptoms
in melanoma, renal cell, ovarian, and colorectal cancer patients....&quot;

http://www.entremed.com/files/2076_slides_ASCO_2009.pdf

*********************************************************************************

Preclinical research looks most promising

http://app2.capitalreach.com/esp1204/servlet/tc?cn=aacr&amp;c=10165&amp;s=20385&amp;e=9605&amp;&amp;

*********************************************************************************

Expect more up to date information about the interim results for ENMD-2076 to be released the first week of June 2010 at this year&#039;s Annual ASCO Meeting.

Good luck and GOD bless,

George]]></description>
		<content:encoded><![CDATA[<p>How many other kinase inhibitors potently affect as many different kinases and cancer types?</p>
<p>********************************************************************************</p>
<p>Striking response in just 7 days for AML leukemia:</p>
<p>&#8220;&#8230;This patient #106, who has a FLT3-ITD mutation, showed a striking reduction in the percentage of circulating blast cells after 7 days treatment with ENMD-2076&#8230;.&#8221;</p>
<p>&#8220;&#8230;A second patient, #120, has a signaling profile very similar to #106,and early follow up indicates that this patient has also had a major response&#8230;&#8221;</p>
<p><a href="http://www.entremed.com/files/enmd_poster_aacr09_p1_leukemia_final_web.pdf" rel="nofollow">http://www.entremed.com/files/enmd_poster_aacr09_p1_leukemia_final_web.pdf</a></p>
<p>*******************************************************************************</p>
<p>Including ovarian cancer:</p>
<p>Watch the video</p>
<p><a href="http://staging.kusa.com/seenon9news/article.aspx?storyid=128349" rel="nofollow">http://staging.kusa.com/seenon9news/article.aspx?storyid=128349</a></p>
<p>&#8220;&#8230;&#8221;I&#8217;m excellent, life is fabulous,&#8221; she told a nurse at the University of Colorado Cancer Center&#8230;.&#8221;</p>
<p>&#8220;&#8230;Thornton and Messersmith were surprised to find the drug known as ENMD-2076 is working well for ovarian cancer patients involved in the study. </p>
<p>&#8220;We have your counts back and they look great,&#8221; Messersmith said to Thornton during a checkup. </p>
<p>&#8220;This is what gets us all up in the morning, to see someone take advantage of it and live life to the fullest,&#8221; Messersmith said&#8230;.&#8221;</p>
<p>*********************************************************************************</p>
<p>&#8220;&#8230;Clinical benefit has been demonstrated with reductions in tumor volume,<br />
reductions in tumor markers, and improvement in cancer-related symptoms<br />
in melanoma, renal cell, ovarian, and colorectal cancer patients&#8230;.&#8221;</p>
<p><a href="http://www.entremed.com/files/2076_slides_ASCO_2009.pdf" rel="nofollow">http://www.entremed.com/files/2076_slides_ASCO_2009.pdf</a></p>
<p>*********************************************************************************</p>
<p>Preclinical research looks most promising</p>
<p><a href="http://app2.capitalreach.com/esp1204/servlet/tc?cn=aacr&#038;c=10165&#038;s=20385&#038;e=9605&#038;&#038;amp" rel="nofollow">http://app2.capitalreach.com/esp1204/servlet/tc?cn=aacr&#038;c=10165&#038;s=20385&#038;e=9605&#038;&#038;amp</a>;</p>
<p>*********************************************************************************</p>
<p>Expect more up to date information about the interim results for ENMD-2076 to be released the first week of June 2010 at this year&#8217;s Annual ASCO Meeting.</p>
<p>Good luck and GOD bless,</p>
<p>George</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on AS-703026 by kinaseNovice</title>
		<link>http://kinasepro.wordpress.com/2009/04/24/as-703026/#comment-31962</link>
		<dc:creator><![CDATA[kinaseNovice]]></dc:creator>
		<pubDate>Fri, 12 Feb 2010 06:58:03 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/?p=973#comment-31962</guid>
		<description><![CDATA[this thing binds totally differently than a hydrozamide would, clue its all about the ATP!]]></description>
		<content:encoded><![CDATA[<p>this thing binds totally differently than a hydrozamide would, clue its all about the ATP!</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on iKinase by officialashleytisdale</title>
		<link>http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31958</link>
		<dc:creator><![CDATA[officialashleytisdale]]></dc:creator>
		<pubDate>Wed, 06 Jan 2010 23:34:43 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31958</guid>
		<description><![CDATA[I saw that...cool app!]]></description>
		<content:encoded><![CDATA[<p>I saw that&#8230;cool app!</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on iKinase by anon</title>
		<link>http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31957</link>
		<dc:creator><![CDATA[anon]]></dc:creator>
		<pubDate>Wed, 06 Jan 2010 16:26:33 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31957</guid>
		<description><![CDATA[You&#039;re alive!]]></description>
		<content:encoded><![CDATA[<p>You&#8217;re alive!</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on iKinase by frmrpfewench</title>
		<link>http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31956</link>
		<dc:creator><![CDATA[frmrpfewench]]></dc:creator>
		<pubDate>Sun, 03 Jan 2010 07:00:33 +0000</pubDate>
		<guid isPermaLink="false">http://kinasepro.wordpress.com/2010/01/02/ikinase/#comment-31956</guid>
		<description><![CDATA[yes!!!! where the eff have you been!]]></description>
		<content:encoded><![CDATA[<p>yes!!!! where the eff have you been!</p>
]]></content:encoded>
	</item>
</channel>
</rss>
